Give weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology
Weekly adalimumab administrations were safe and effective in controlling both articular and ocular inflammation. In cases where the disease is poorly controlled with regular biweekly administrations, we encourage escalating adalimumab treatment to weekly administration before adding other therapies or switching to different biologics.
Authors
- Debora Curci (ORCID: https://orcid.org/0000-0002-3273-9489)
- Tomoyuki Mizuno (ORCID: https://orcid.org/0000-0002-8471-9826)
- Gabriele Stocco (ORCID: https://orcid.org/0000-0003-0964-5879)
- Francesca Burlo (ORCID: https://orcid.org/0000-0002-8915-5855)
- Serena Pastore (ORCID: https://orcid.org/0000-0003-4697-0777)
- Paolo Dalla Zuanna
- Kei Irie (ORCID: https://orcid.org/0000-0001-9878-4672)
- Alberto Tommasini
- Andrea Taddio
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- University of Trieste (IT)
- IRCCS Materno Infantile Burlo Garofolo (IT)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1186/s13075-025-03688-4
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero della Salute
- Agenzia Italiana del Farmaco, Ministero della Salute